Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
TenX Biopharma
Philadelphia, Pennsylvania, United Statesprnewswire.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
TenX Biopharma was a biopharmaceutical company focused on the late-stage development and launch of novel cancer products. Its most notable activity was acquiring exclusive worldwide rights from Genmab to develop and commercialize HuMax-CD4® (zanolimumab), a fully human monoclonal anti-CD4 antibody for T-cell lymphomas. As of 2010, zanolimumab was in Phase III trials for cutaneous T-cell lymphoma and Phase II trials for peripheral T-cell lymphoma. No recent clinical or business updates are available after this period.
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodyAntibody
- Industry
- Biotech
02
Partnerships
Genmab
Beyond the preview
Go deeper on TenX Biopharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TenX Biopharma.